Učitavanje...
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma
Anti-angiogenic therapy is a promising therapeutic strategy for the highly vascular and malignant brain tumor, glioblastoma (GBM), although current clinical trials have failed to demonstrate an extension in overall survival. The small molecule tyrosine kinase inhibitor axitinib that targets vascular...
Spremljeno u:
| Izdano u: | J Neurooncol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751887/ https://ncbi.nlm.nih.gov/pubmed/25213669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1612-1 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|